Generalized anxiety disorder is characterized by excessive anxiety
and worry about everyday life events with no apparent reason. The
patient cannot stop worrying about health, family, money, or work
and eventually anxiety dominates the person thinking, that interfere
with daily functioning of person. Symptoms of generalized anxiety
disorder includes an unrealistic view of problems, muscle tension,
headache, sweating, and tiredness. Additionally, rarely GAD occurs
alone as it often accompanied by other anxiety disorder, substance
abuse, and depression. Number of factors are responsible to develop
GAD which includes genetics, brain chemistry, and environmental
factors such as trauma and stressful event, family background, or
life experiences.
Report Overview @
https://www.transparencymarketresearch.com/generalized-anxiety-disorder-market.html
The disorder comes on progressively and can arise across the life
cycle, though the risk is highest between childhood and middle age.
GAD is diagnosed when a person worries excessively of everyday
problems for more than six months and has three or more symptoms.
According to Centers for Disease Control and Prevention (CDC),
prevalence of anxiety disorder in Europe is over 15 % of total Europe
population. In addition, CDC stated that prevalence of disorder is
more in women than men. Generally, psychotherapy is preferable to GAD
patient before medication which teaches a person different ways of
reacting, and thinking in various life situations.
Generalized anxiety disorder market is segmented into therapeutics,
and geography. The therapeutics market is segmented into
antidepressant, buspirone, and benzodiazepines. Antidepressants
further segmented into selective serotonin reuptake inhibitor (SSRI),
and serotonin norepinephrine reuptake inhibitor(SNRI).
Benzodiazepines includes alprazolam (Niravam, Xanax),
chlordiazepoxide (Librium), diazepam (Valium) and lorazepam. However,
benzodiazepines can be habit forming hence, generally used for short
term basis and consider as a last choice of treatment. Antidepressant
are first line therapy for GAD patient hence, hold the largest market
share globally.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9518
Geographically, generalized anxiety disorder market segmented into
North America, Europe, Asia Pacific, Latin America, Middle East and
Africa, and Rest of the World (RoW). North America dominates the
global generalized anxiety market due to increasing incidence of
anxiety disorders, and more awareness in people related to anxiety
and it is expected to maintain the position during forecast period.
However, Asia Pacific market is expected to grow at a faster rate due
to changing lifestyle lead to increasing stress, and growing
facilities to detect anxiety disorders.
Some of the major driving factors to propel the generalized anxiety
disorders market are increasing incidence rate due to more stressful
life, Sedentary lifestyle, and presence of strong pipeline. According
to National Institute of Mental Health, every year GAD affects
minimum 6.8 million adults, or 3.1% of the U.S. population. In the
National Comorbidity Survey carried out in 2005, 58% of patients
diagnosed with major depression were found to have an anxiety
disorder; among these patients, the rate of comorbidity with GAD was
17.2%. However, poor diagnosis rate as no single diagnosis test is
available to detect generalized anxiety disorder, affectivity of
psychotherapy, and side effects of medications such as habit forming
nature, dry mouth, and nausea could restraint the market growth.
Focusing on emerging countries such as BRICS countries would create
an opportunity for a market players.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=9518<ype=S
Some of the key players of the global generalized anxiety disorder
market are Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals
Limited, Pfizer, Inc., Abbott Laboratories, Baxter International,
Bristol-Myers Squibb, Actavis Pharmaceutical Company, F. Hoffmann-La
Roche, Recordati Rare Diseases, Noven Pharmaceuticals, Inc., Sumitomo
Dainippon Pharma, and Shionogi and Company.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment